The ProcartaPlex Human Immuno-Oncology Checkpoint Panel 3 9plex enables cancer research by analyzing nine protein immune-oncology targets in a single well using Luminex xMAP technology. Simultaneous detection of these targets can help to understand the role of the B7 family of immune checkpoint regulators in controlling and suppressing immune responses of T cells and NK cells.

This panel is combinable with simplexes and other panels such as the Human Immuno-Oncology Checkpoint Panel 1 14plex and Human Immuno-Oncology Checkpoint Panel 2 14plex, providing 28 additional protein targets for immune checkpoint profiling.

ProcartaPlex preconfigured panels are extensively tested for analyte combinability, interference, and cross-reactivity to provide the highest level of validation and precision. ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine) and are supplied with the necessary reagents to perform the assay. Visit our ProcartaPlex Immunoassays page for more information and available products.

Target list [bead region]: B7-H6 [42], CD276 (B7-H3) [72], CD47 (IAP) [74], CD48 (BLAST-1) [19], CD134 (OX40) [55], ICOS Ligand (B7-H2) [34], TIMD-4 [39], S100A8/A9 [76], VISTA (B7-H5) [64]

About ProcartaPlex assays for the Luminex platform

ProcartaPlex immunoassays are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously using a Luminex instrument. ProcartaPlex multiplex assays require as little as 25 μL of plasma or serum, or 50 μL of cell culture supernatant, and just four hours to obtain analyzed results.

• Reproducible, reliable results—validated as a panel to the highest industry standard, including protein target combinability and cross-reactivity testing
• More results per sample—measure multiple protein targets simultaneously in a single 25–50 μL sample
• Well-established Luminex technology—the most referenced multiplexing platform for protein detection and quantitation

ProcartaPlex assays utilize Luminex xMAP (multianalyte profiling) technology for the simultaneous detection and quantitation of up to 80 protein targets in a single 25–50 μL sample—from plasma, serum, cell culture supernatants, and other bodily fluids.

The Luminex MagPlex superparamagnetic microsphere beads in the ProcartaPlex assay are internally dyed with precise proportions of red and infrared fluorophores to create 100 spectrally unique signatures that can be identified by the Luminex xMAP detection systems (Luminex 200, FLEXMAP 3D, and MAGPIX systems). Similar to a sandwich ELISA, the ProcartaPlex assay uses matched antibody pairs to identify the protein of interest. In a multiplexed assay, each spectrally unique bead is labeled with antibodies specific for a single target protein, and bound proteins are identified with biotinylated antibodies and streptavidin–R-phycoerythrin (RPE). The conjugation of protein-specific antibodies to a distinct bead allows for analysis of multiple targets in a single well.

The most significant difference between a ProcartaPlex assay and ELISA is that the capture antibody in the ProcartaPlex assay is conjugated to a magnetic bead and not adsorbed to the microplate well, so the ProcartaPlex assay reagents are free-floating in the solution. For detection, the Luminex 200 instrument, for example, contains two lasers, one to distinguish the spectral signature of each bead and the second to quantify the amount of RPE fluorescence, which is proportional to the amount of protein present in the sample. ProcartaPlex multiplex assays can profile more target proteins using significantly less sample in the same time that it takes to perform a traditional sandwich ELISA.

ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine). Visit thermofisher.com/procartaplex for more information and available products.